Global Alliance for Regenerative Medicine Report issue

Academic/Hospital

Organization Overview

First Clinical Trial
2017
NCT03090672
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Global Alliance for Regenerative Medicine (GARM) | Global Alliance Regenerative Medicine

Active Ingredients

Drugs in Other Trials (2)

autologous stromal vascular fraction (1 trial)

stromal vascular fraction (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 2